FACULTY
Leonard B. Bacharier, MD
Janie Robinson and John Moore Lee Chair in Pediatrics
Professor of Pediatrics
Director, Center for Pediatric Asthma Research
Scientific Director, Center for Clinical and Translational Research
Section Chief, Pediatric Allergy & Immunology
Division of Allergy, Immunology, and Pulmonary Medicine
Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center
Nashville, TN
Geoffrey Chupp, MD
Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine)
Director, Yale Center for Asthma and Airways Disease (YCAAD)
Director, Pulmonary Function Laboratory
Yale-New Haven Hospital
New Haven, CT
PROGRAM OVERVIEW
This enduring activity will allow the participant to focus on understanding the strategies for effectively managing moderate-to-severe asthma, to describe the clinical evidence for the use of biologics, to use evidence based strategies to select the optimal therapy for the right patient at the right time, and to understand strategies to provide more effective patient communication to promote better outcomes. Listen to experts discuss the etiopathology of asthma; the different treatment options available; and learn about the various biologics available to manage more advanced and uncontrolled moderate-to-severe asthma, as well as what patient-specific considerations might be taken into account when deciding to use biologics.
TARGET AUDIENCE
This educational activity is designed to meet the identified needs of U.S.-based allergists, immunologists, respiratory technicians, and other health care providers involved in the care of adult and pediatric patients with moderate-to-severe asthma.
LEARNING OBJECTIVES
- Describe the clinical evidence for approved and investigational biologics for the treatment of moderate-to-severe asthma
- Identify evidence-based strategies to effectively select the right therapy for the right patient at the most optimal point of care
- Detail strategies to provide more effective patient-centered communication and education to promote better outcomes
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Leonard B. Bacharier, MD discloses that he is a consultant for AstraZeneca, GlaxoSmithKline, Avillion, DBC Technologies, Aravax, Vertex Pharmaceuticals, Genentech/ Novartis, Regeneron Pharmacuticals, Inc., Sanofi, Recludix, DBV Technologies and OM Pharma. He has served on the speakers’ bureau for Sanofi and Regeneron. He has conducted clinical trials and research grants for Sanofi, Regeneron, and AstraZeneca.
Geoffrey Chupp, MD discloses that he is a consultant for Genentech, AstraZeneca, Sanofi Genzyme, Regeneron, GlaxoSmithKlein, Merck, RAPT Therapeutics, and NHLBI (Precise).
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of the activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Michael L. Andria, Pharm. D, Medical Director of Med Learning Group, has nothing to disclose.
- Dominique Barton, RN, has nothing to disclose
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Associate Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected].
RELEASED DATE: March 11, 2024
EXPIRATION DATE: March 11, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
